Artemis Medicare Services Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026 (Q4FY26), pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 162A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The report, prepared by CARE Ratings Limited in its capacity as Monitoring Agency, pertains to the utilization of proceeds from the company's Preferential Issue of Compulsorily Convertible Debentures aggregating to Rs. 330.00 crore. The Audit Committee reviewed the report at its meeting held on May 8, 2026.

Issue and Issuer Details

The Preferential Issue was undertaken by Artemis Medicare Services Limited, a company operating in the Healthcare Services – Hospital sector. The promoters are Mr. Onkar Kanwar and Constructive Finance Private Limited. The key details of the issue are summarized below:

Utilization of Issue Proceeds

During Q4FY26, the company utilized Rs. 74.62 crore towards supporting acquisition, expansion, and capital expenditure requirements. Specifically, the company signed a Medical Service Agreement (MSA) with Dr Vidyasagar Kaushalya Devi Memorial Health Centre and paid an additional advance revenue share of Rs. 74.62 crore as per the terms of the MSA. No amount was utilized towards General Corporate Purposes during the quarter. The following table captures the progress in utilization of the issue proceeds:

Deployment of Unutilized Proceeds

The total unutilized amount of Rs. 193.11 crore as at the end of the quarter has been deployed across fixed deposits with multiple banks. The company also received interest of Rs. 0.05 crore on matured Fixed Deposits, which has been reinvested in Fixed Deposits. The details of the deployment are as follows:

Compliance and Deviation Status

The Monitoring Agency confirmed that all utilization is in accordance with the disclosures in the Offer Document, with no deviations observed from earlier monitoring agency reports. The means of finance for the disclosed objects have not changed. No favorable or unfavorable events affecting the viability of the objects were reported, and no other material information affecting investor decision-making was identified. Both objects of the issue — acquisition, expansion, and capital expenditure requirements, as well as General Corporate Purposes — are listed as ongoing, with a completion date of May 15, 2026 as per the Offer Document, and no delay in days or months has been reported.

The Chartered Accountant's certificate relied upon for this report was issued by M/s T R Chadha & Co. LLP, Statutory Auditors of Artemis Medicare Services Limited, dated April 30, 2026. The report notes that the CA certificate provides limited assurance, and the procedures performed are less in extent than those for a reasonable assurance engagement.

Artemis Medicare Services Limited has announced an earnings conference call for investors and analysts to discuss the company's operational and financial performance for Q4 and FY26. The call is scheduled to be held on Monday, May 11, 2026, at 11:00 AM IST, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was communicated via an official intimation signed by Poonam Makkar, Company Secretary and Compliance Officer, dated May 5, 2026.

Conference Call Details

The earnings call will be hosted by Anand Rathi Research. The following table summarises the key details of the scheduled event:

Key Participants

Senior leadership from Artemis Medicare Services will be present on the call to address queries from investors and analysts:

• Dr. Devlina Chakravarty — Managing Director
• Mr. Sanjiv Kumar Kothari — Chief Financial Officer
• Mr. Rudra Narayan Acharjee — Head – Investor Relations, M&A and Organization Growth Strategy

Access Details

Participants can join the conference call through the following dial-in numbers:

For further information, participants may contact the call co-ordinator, Himanshu Binani, at Office No: (022) 6626 6712 or Mobile: 7381039698. The company has noted that the schedule is subject to changes in case of exigencies on the part of analysts, investors, or the company.